Advertisement

Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

12:04 EDT 22nd May 2013 | BioPortfolio

Summary

The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Conditions

Depression

Intervention

SEROQUEL XR (quetiapine), SEROQUEL IR (quetiapine), radioligand [11C]raclopride

Location

Research Site
Stockholm
Sweden

Status

Completed

Source

AstraZeneca

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

Decompression

Decompression external to the body, most often the slow lessening of external pressure on the whole body (especially in caisson workers, deep sea divers, and persons who ascend to great heights) to prevent DECOMPRESSION SICKNESS. It includes also sudden accidental decompression, but not surgical (local) decompression or decompression applied through body openings.

Depression, Postpartum

Depression in POSTPARTUM WOMEN, usually within four weeks after giving birth (PARTURITION). The degree of depression ranges from mild transient depression to neurotic or psychotic depressive disorders. (From DSM-IV, p386)

Raclopride

A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.

Depression

Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.

Imipramine

The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.

Clinical Trials [ 733 Associated Clinical Trials listed on BioPortfolio]

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 we...

Seroquel- Agitation Associated With Dementia

The purpose of this study is to determine how safe and effective Seroquel (quetiapine fumarate) is compared to placebo (a non-drug tablet) for a period of up to 10 weeks in the treatment...

Seroquel in Bipolar Depression Versus Lithium

This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followe...

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

This study is designed to assess the use of pramipexole dihydrochloride and quetiapine (Seroquel) XR as combination therapy for bipolar depression. The proposed benefit of the combination...

Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)

This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of...

PubMed Articles [ 3695 Associated PubMed Articles listed on BioPortfolio]

Quetiapine (Seroquel) and QT-interval prolongation.

Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study.

Abstract Objective: To evaluate the efficacy and safety of 750 mg/day quetiapine fumarate (Seroquel * ) in the treatment of Chinese Han patients with schizophrenia. Methods: In this 6-week, multicente...

The role of quetiapine extended release in the treatment of bipolar depression.

Bipolar disorder is a common, recurrent, and chronic condition associated with significant morbidity and reduced longevity mainly due to the depressive pole of the illness. Despite the great need for...

A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder.

Objective. To examine the longer-term efficacy of quetiapine monotherapy in bipolar depression in a preplanned pooling of data from the EMBOLDEN I and II studies. Methods. Patients (N = 584) with bipo...

Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.

Quetiapine is an established drug for treatment of schizophrenia, bipolar disorder, and major depressive disorder. While initially manufactured as an immediate-release (IR) formulation, an extended-re...

More From BioPortfolio on "Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL"

Search BioPortfolio:
Advertisement
Advertisement